In today’s briefing:
- HSIE Results Daily: Max Healthcare, Fine Organic Industries, KNR Constructions, Ahluwalia…
- HSIE Results Daily: Max Healthcare, Fine Organic Industries, KNR Constructions, Ahluwalia…
- HSIE Results Daily: Repco Home Finance
- Rossari Biotech Ltd | Q3FY22 Result Update
HSIE Results Daily: Max Healthcare, Fine Organic Industries, KNR Constructions, Ahluwalia…
- Ahluwalia Contracts: Ahluwalia Contracts (AHLU) reported revenue/EBITDA/APAT (miss)/beat of (4)/(1)/7%.
- AHLU is confident of crossing INR 25bn+ in revenue for FY22, backed by order backlog (OB) of INR 67bn and an L1 of INR 7bn.
- 15% of the OB is fixed price contracts and exposed to price volatility.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
HSIE Results Daily: Max Healthcare, Fine Organic Industries, KNR Constructions, Ahluwalia…
- Ahluwalia Contracts: Ahluwalia Contracts (AHLU) reported revenue/EBITDA/APAT (miss)/beat of (4)/(1)/7%.
- AHLU is confident of crossing INR 25bn+ in revenue for FY22, backed by order backlog (OB) of INR 67bn and an L1 of INR 7bn.
- 15% of the OB is fixed price contracts and exposed to price volatility.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
HSIE Results Daily: Repco Home Finance
- Given the impending appointment of a new MD & CEO from 1 March, we await a roadmap from the new management.
- We hack our FY22/FY23/FY24 earnings estimates by 24%/15%/14% due to elevated credit costs and muted loan growth and maintain ADD with a revised target price of INR328 (0.9x Sep-23 ABVPS).
- Repco Home Finance: REPCO’s Q3 earnings disappointed our estimates due to elevated provisioning and subdued loan growth (-2.3% YoY).
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Rossari Biotech Ltd | Q3FY22 Result Update
- Input cost inflation continues to weigh on margins.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Before it’s here, it’s on Smartkarma
